Multivariate analyses of PFS in the ITT population∗ based on IRC assessment
| Factor . | Parameter estimate (SE) . | HR (95% CI) . | P value . |
|---|---|---|---|
| Imputed MRD status at randomization (MRD− vs MRD+) | −2.08 (0.203) | 0.13 (0.09-0.19) | <.001 |
| Prior response after transplant/induction (VGPR or CR vs PR) | −0.47 (0.080) | 0.62 (0.53-0.73) | <.001 |
| Preinduction ISS stage (I vs III) | −0.41 (0.098) | 0.67 (0.55-0.81) | <.001 |
| Pre-induction ISS stage (II vs III) | −0.13 (0.088) | 0.88 (0.74-1.04) | .136 |
| Cytogenetic group at initial diagnosis (unclassifiable vs standard-risk) | −0.08 (0.106) | 0.93 (0.75-1.14) | .461 |
| Cytogenetic group at initial diagnosis (standard-risk vs high-risk) | −0.35 (0.097) | 0.71 (1.17-1.71) | < .001 |
| Prior exposure to a PI (no vs yes) | −0.12 (0.106) | 0.88 (0.92-1.39) | .245 |
| Treatment assigned at randomization (ixazomib vs placebo) | −0.36 (0.076) | 0.70 (0.60-0.81) | <.001 |
| Factor . | Parameter estimate (SE) . | HR (95% CI) . | P value . |
|---|---|---|---|
| Imputed MRD status at randomization (MRD− vs MRD+) | −2.08 (0.203) | 0.13 (0.09-0.19) | <.001 |
| Prior response after transplant/induction (VGPR or CR vs PR) | −0.47 (0.080) | 0.62 (0.53-0.73) | <.001 |
| Preinduction ISS stage (I vs III) | −0.41 (0.098) | 0.67 (0.55-0.81) | <.001 |
| Pre-induction ISS stage (II vs III) | −0.13 (0.088) | 0.88 (0.74-1.04) | .136 |
| Cytogenetic group at initial diagnosis (unclassifiable vs standard-risk) | −0.08 (0.106) | 0.93 (0.75-1.14) | .461 |
| Cytogenetic group at initial diagnosis (standard-risk vs high-risk) | −0.35 (0.097) | 0.71 (1.17-1.71) | < .001 |
| Prior exposure to a PI (no vs yes) | −0.12 (0.106) | 0.88 (0.92-1.39) | .245 |
| Treatment assigned at randomization (ixazomib vs placebo) | −0.36 (0.076) | 0.70 (0.60-0.81) | <.001 |
Patients in ITT population with nonmissing information.